Скачать или смотреть HOT TOPICS | CAR-T | Solid Tumors Success | When?

The potential application of CAR-T in solid tumors will be a game-changer if it occurs. The panel explores the prospects of solid tumor success and what the barriers have been. Questions include:
 - How would industry and investor strategy for CAR-T and solid tumors be characterized? Has it changed in the last couple of years?
Does the lack of tumor antigen specificity in solid tumors mean that lessons from liquid tumor CAR-T constructs will not translate well and we have to start over?
Whether due to antigen heterogeneity, a hostile tumor micro-environment, or other factors are some specific solid tumors more attractive opportunities than others for CAR-T therapy development?
Given the many challenges that CAR-T faces in solid tumors, does the use of combination therapies from the start, for example, to mitigate TME effects, offer a more compelling opportunity.

Moderator: Oladapo Yeku, MD, PhD, Clinical Assistant in Medicine, MGH
Jennifer Brogdon, Executive Director, Head of Cell Therapy Research, Exploratory Immuno-Oncology, NIBR
Knut Niss, PhD, CTO, Mustang Bio
Barbra Sasu, PhD, CSO, Allogene
Jay Short, PhD, Chairman, CEO, Cofounder, BioAlta, Inc.